Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACAM2000 vaccination for VIGIV production
NCT01158157Phase 3Completed
- Sponsor
- Emergent BioSolutions
- Start
- Sep 2010
- Primary completion
- Feb 2012
- Modality
- Prophylactic Vaccines, DNA Vaccines, Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 3 trial of smallpox (vaccinia) vaccine, live in smallpox, sponsored by Emergent BioSolutions. Started Sep 2010; status: completed.
02
Drugs
smallpox (vaccinia) vaccine, live
03
Conditions
smallpox
Beyond the preview
Go deeper on NCT01158157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01158157.